News ReleaseView printer-friendly version << Back
AcelRx Pharmaceuticals Announces Publication of Clinical Data on Decreased Postoperative Opioid Requirements and Enhanced Postanesthesia Recovery Following Perioperative Use of DSUVIA®
The article entitled "A Medication Use Evaluation of Sufentanil Sublingual Tablet 30 mcg for the Perioperative Management of Surgical Pain" by lead author
The evaluation focused on 140 patients who were dosed with SST 30 mcg compared to 158 patients who had been dosed with traditional IV opioids during the same time period undergoing the same surgical procedures. Key findings included the following:
- Intraoperative IV opioid use – patients in the control group overall received 66% higher mean dosing of intraoperative IV opioids compared to patients receiving SST (p<0.001).
- Postoperative opioid use – the mean opioid requirement of the SST group was less than half of the control group (p<0.001), with orthopedic surgery patients having the largest decrease (69%).
- PACU time to discharge – Phase 1 recovery time in the PACU was reduced by an average of 14 minutes across patients in the SST group compared with the control group (p<0.001), with the largest decrease in recovery time observed among abdominal surgery patients (23 minutes; 25% reduction).
- Respiratory depression – 3 patients in the control group required naloxone use for respiratory depression whereas no patients in the SST group required naloxone use.
The authors concluded that overall, SST dosed preoperatively or intraoperatively, significantly reduced both PACU opioid dosing requirements and Phase 1 unit discharge time compared to control patients receiving standard IV opioids intraoperatively. SST was well tolerated with no significant adverse events. In addition, the authors noted that decreasing discharge time per patient can have a substantial financial impact when multiplied over thousands of patients each year taking into account surgical throughput inefficiency that congestion in the PACU creates. Study limitations include that it was a single-center, retrospective study of SST dosing in a surgical patient population and both inpatient and outpatient surgery data was combined. The study did not control for whether patients were opiate naïve or opiate tolerant in the treatment groups, however, there is no reason for these patients to be present at a substantially higher frequency in either group. AcelRx did not provide funding for the conduct of the evaluation but did fund medical writing support. AcelRx did not provide any compensation to the authors for the evaluation.
"We are thrilled this clinical data supports DSUVIA as a well-tolerated and effective pain management solution across a wide variety of both inpatient and outpatient surgical procedures, and also indicates shorter patient recovery time and economic benefits for hospitals," said Dr. Pamela Palmer, AcelRx Chief Medical Officer and co-founder. "Importantly, the findings of reduced overall IV opioid use and PACU discharge time are consistent with other recently published clinical data on the use of DSUVIA in the perioperative environment."
About DSUVIA (sufentanil sublingual tablet), 30 mcg
DSUVIA®, known as DZUVEO™ in
View original content to download multimedia:http://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-announces-publication-of-clinical-data-on-decreased-postoperative-opioid-requirements-and-enhanced-postanesthesia-recovery-following-perioperative-use-of-dsuvia-301190454.html
Raffi Asadorian, CFO, AcelRx, email@example.com; Brian Korb, Solebury Trout, 646-378-2923, firstname.lastname@example.org